Cell and Gene Therapies Demand a Robust System
Miltenyi Biotec
Standardizing your CGT platform to ensure consistency during experiments is essential for improving future clinical outcomes
CAR-T
Modified CAR-T Therapy Abates Myasthenia Gravis Symptoms
National Institutes of Health
Trial showed that mRNA-led CAR-T therapy may be a safe and durable treatment option for this rare disease
Controlling Conditions for CAR T Cells
Today's Clinical Lab
Download this application note for guidelines on ensuring a constant and stable environment for your CAR T cells
A Bull’s Eye Approach for Targeted Cancer Therapies
Mark M. Garner, PhD
Collaboration is at the heart of developing and deploying new targeted cancer solutions
Simple Blood Test Predicts Neurotoxic Complications of CAR-T Cell Therapy
Washington University School of Medicine
Identifying high-risk patients could improve cancer care
Solving Cell Therapy’s “Garbage in, Garbage out” Problem with Automation
Tony Ward
Despite industry’s emphasis on cell engineering and expansion, better starting materials are the foundation of the manufacturing revolution
Sharpening a Double-Edged Sword: Bispecific CAR-T Cancer Therapies
Today's Clinical Lab
Join Today's Clinical Lab and David Miklos, MD, PhD, to discuss recent advances in bispecific CAR-T therapy and biomarkers for characterizing CAR-T product quality
Exploring Alternatives to CRISPR Gene Editing Techniques
Marwan Alsarraj, MS
Transposons have the potential to make DNA editing easier, cheaper, and safer
Toward Off-the-Shelf T-Cell Therapies: Looking to the Future
Manher (AJ) Joshi, MD
Off-the-shelf allogeneic T-cell therapies have the potential to leverage the power of a healthy donor’s immune system
Novel Complex Cell Manufacturing
Scott D. Hanton, PhD
Challenges and critical considerations for the manufacturing of cellular therapies